Promising CML combo study halted early – only 7 patients enrolled
NCT ID NCT04216563
First seen Jan 11, 2026 · Last updated Jun 12, 2026 · Updated 25 times
Summary
This study tested whether adding a new drug (ABL001) to standard CML therapy could help patients with small amounts of remaining leukemia. Only 7 people took part before the study was stopped early. The goal was to see if the combination could improve molecular responses and possibly allow patients to stop treatment later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHILADELPHIA CHROMOSOME NEGATIVE, BCR-ABL1 POSITIVE CHRONIC MYELOGENOUS LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.